Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Douglas Haney"'
Autor:
Kamrul Islam, Motaher Hossain, Meagan Kelly, Leslie M Mayo Smith, Richelle C Charles, Taufiqur Rahman Bhuiyan, Pavol Kováč, Peng Xu, Regina C LaRocque, Stephen B Calderwood, Jakub K Simon, Wilbur H Chen, Douglas Haney, Michael Lock, Caroline E Lyon, Beth D Kirkpatrick, Mitchell Cohen, Myron M Levine, Marc Gurwith, Jason B Harris, Firdausi Qadri, Edward T Ryan
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 12, Iss 4, p e0006376 (2018)
BACKGROUND:Cholera is an acute voluminous dehydrating diarrheal disease caused by toxigenic strains of Vibrio cholerae O1 and occasionally O139. A growing body of evidence indicates that immune responses targeting the O-specific polysaccharide (OSP)
Externí odkaz:
https://doaj.org/article/5a7a697cf70e4170a1b24a53b409d81b
Autor:
Paul-Andre de Lame, Douglas Haney, James M. McCarty, David Cassie, Sean Bennett, Lisa Bedell, Michael Lock
Publikováno v:
Expert review of vaccines. 21(1)
INTRODUCTION Cholera remains endemic in >50 countries, putting millions at risk, especially young children for whom killed vaccines offer limited protection. An oral, live attenuated vaccine - CVD 103-HgR (Vaxchora vaccine) - was licensed by the US F
Autor:
Marc Gurwith, Mitchell B. Cohen, Beth D. Kirkpatrick, Jakub K. Simon, Marcelo B. Sztein, Douglas Haney, Jason B. Harris, Glenn Ishioka, Myron M. Levine, Caroline E. Lyon, Wilbur H. Chen, Michael Lock
Publikováno v:
Vaccine. 36:2768-2773
Background The single-dose live attenuated vaccine CVD 103-HgR protects against experimental Vibrio cholerae infection in cholera-naive adults for at least 6 months after vaccination. While vaccine-induced vibriocidal seroconversion is associated wit
Autor:
Michael Lock, Wilbur H. Chen, Beth D. Kirkpatrick, Douglas Haney, Myron M. Levine, Marc Gurwith, Caroline E. Lyon, Mitchell B. Cohen, Sharon M. Tennant, Jakub K. Simon, David Galloway, Robert A. Kessler, R H Hall, Flora Szabo, Marcela F. Pasetti, Rebecca C. Brady
Publikováno v:
Clinical Infectious Diseases. 62:1329-1335
Background. No licensed cholera vaccine is presently available in the United States. Cholera vaccines available in other countries require 2 spaced doses. A single-dose cholera vaccine that can rapidly protect short-notice travelers to high-risk area
Publikováno v:
Clinical and Vaccine Immunology : CVI
Immunologic correlates of protection can be used to infer vaccine efficacy for populations in which challenge trials or field studies are infeasible. In a recent cholera challenge trial (W. H. Chen et al., Clin Infect Dis 62:1329–1335, 2016, https:
Autor:
Wilbur H. Chen, Jason B. Harris, Beth D. Kirkpatrick, Mitchell B. Cohen, Marc Gurwith, Stephen B. Calderwood, Leslie M. Mayo-Smith, Michael Lock, Douglas Haney, Myron M. Levine, Jakub K. Simon, Caroline E. Lyon
Publikováno v:
Clinical and Vaccine Immunology. 24
One potential advantage of live attenuated bacterial vaccines is the ability to stimulate responses to antigens which are only expressed during the course of infection. To determine whether the live attenuated cholera vaccine CVD 103-HgR (Vaxchora) r
Autor:
Beth D. Kirkpatrick, Leslie M. Mayo Smith, Pavol Kováč, Marc Gurwith, Jason B. Harris, Stephen B. Calderwood, Motaher Hossain, Kamrul Islam, Mitchell B. Cohen, Peng Xu, Jakub K. Simon, Myron M. Levine, Wilbur H. Chen, Caroline E. Lyon, Michael Lock, Edward T. Ryan, Firdausi Qadri, Douglas Haney, Regina C. LaRocque, Richelle C. Charles, Taufiqur Rahman Bhuiyan, Meagan Kelly
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 12, Iss 4, p e0006376 (2018)
PLoS Neglected Tropical Diseases
PLoS Neglected Tropical Diseases
Background Cholera is an acute voluminous dehydrating diarrheal disease caused by toxigenic strains of Vibrio cholerae O1 and occasionally O139. A growing body of evidence indicates that immune responses targeting the O-specific polysaccharide (OSP)